Clinical Drug Investigation

, Volume 16, Issue 1, pp 80–83 | Cite as

Use of Transdermal Fentanyl in Cancer Patients with Intestinal Problems Four Case Studies

  • Peter Naughton
  • Patricia Horan
Case Report Series


Morphine Fentanyl Adis International Limited Cancer Pain Hydromorphone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997 May; 13(5): 254–61PubMedCrossRefGoogle Scholar
  2. 2.
    Megens AAHP, Artois K, Vermiere J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998: 15(4): 253–8PubMedCrossRefGoogle Scholar
  3. 3.
    Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicentre study in patients with cancer pain. Pain 1996; 64: 527–34PubMedCrossRefGoogle Scholar
  4. 4.
    Zech DFJ, Grond SUA, Lunch J, et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992; 50: 293–301PubMedCrossRefGoogle Scholar
  5. 5.
    Twycross R. Symptom management in advanced cancer. Oxford: Radcliffe Medical Press, 1997: 257Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Peter Naughton
    • 1
  • Patricia Horan
    • 1
  1. 1.Portlaoise General HospitalPortlaoiseRepublic of Ireland

Personalised recommendations